medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2017, Number 1

<< Back Next >>

Acta Med 2017; 15 (1)

High suspicion of congenital metabolic diseases in the population of Jewish descent of Hospital Angeles Lomas

Medina DAC, Oldak KB, Vela AM, Ibarra GI, Fernández LC, Oldak SD

Language: Spanish
References: 22
Page: 32-35
PDF size: 119.16 Kb.


ABSTRACT

Background: The application of the neonatal screening and its extension to diseases not identified by the classic method constitutes a challenge that has led to the application of new technologies, such as the multiple platform and the tandem mass spectrometry. A predisposition to these pathologies has been identified in certain communities not previously studied, like the Jewish one; this makes their study essential for their timely diagnosis. Objective: To report the number of neonatal screening assays with suspicious reports for a congenital metabolic disease in those patients of Jewish ascent in the Angeles Lomas Hospital, and to compare it to the rest of the cases. Material and methods: We analyzed all the neonatal screenings performed between January 2010 and December 2014 at the Angeles Lomas Hospital. The suspicious results were recorded in a database, analyzing sex and ethnicity. Results: 4,749 neonatal screenings were analyzed; 1,425 were of Jewish ascendant. One hundred seventy-two screenings were suspicious, but only 27 were consistent in the second test. Of them, 50% of the females and 41% of the males were Jewish. Conclusion: We observed an elevated incidence of suspicious cases of congenital diseases in population with Jewish ancestry, especially for G6PD and MCADD.


REFERENCES

  1. Scriver CC. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants, by Robert Guthrie and Ada Susi. Pediatrics. 1963; 32: 338-343.

  2. Natowicz M. Newborn screening —setting evidence-based policy for protection. N Engl J Med. 2005; 353 (9): 867-870.

  3. Berry SA. Newborn screening. Clin Perinatol. 2015; 42: 441-453.

  4. Therrell BL, Padilla CD, Loeber JG, Kneisser I, Saadallah A. Borrajo JC et al. Current status of newborn screening worldwide: 2015. Semmin Perinatol. 2015; 39: 171-187.

  5. Dussault JH. The anecdotal history of screening for congenital hypothyroidism. J Clin Endocrinol Metab. 1999; 84: 4332-4334.

  6. Delange F. Neonatal screening for congenital hypothyroidism: results and perspectives. Horm Res. 1997; 48: 51-61.

  7. AAP Newborn Screening Task Force. Saving the family from birth to the medical home: newborn screening: a blueprint for the future –a call for a national agenda on state newborn screening programs. Pediatrics. 2000; 106: 389-422.

  8. Fernández-Lainez C, Aguilar-Lemus JJ, Vela-Amieva M, Ibarra-González I. Tandem mass spectrometry newborn screening for inborn errors of intermediary metabolism: abnormal profile interpretation. Curr Med Chem. 2012; 19: 4511-4522.

  9. Ibarra-González I, Fernández-Lainez C, Belmont-Martínez L, Guillén-López S, Monroy-Santoyo S, Vela-Amieva M. Caracterización de errores innatos del metabolismo intermediario en pacientes mexicanos. An Pediatr (Barc). 2014; 80: 310-316.

  10. Raise GM, Steiner RD. Inborn errors of metabolism (metabolic disorders). Pediatr Rev. 2016; 37: 3-15.

  11. Norma Oficial Mexicana NOM-007-SA2-1993. Atención de la mujer durante el embarazo, parto y puerperio y recién nacido. Criterios y procedimientos para la prestación del servicio. Diario Oficial de la Federación, órgano del Gobierno Constitucional de los Estados Unidos Mexicanos, tomo CDXCDI; 1995.

  12. Norma Oficial Mexicana NOM-034-SSA2-2002. Para la prevención y control de los defectos al nacimiento. Diario Oficial de la Federación, órgano del Gobierno Constitucional de los Estados Unidos Mexicanos, tomo DLXXVII; 2003.

  13. Norma Oficial Mexicana NOM-034-SSA2-2013. Para la prevención y control de los defectos al nacimiento. Diario Oficial de la Federación, órgano del Gobierno Constitucional de los Estados Unidos Mexicanos, tomo. DCCXXXII; 2014.

  14. Trigo-Madrid M, Díaz-Gallardo J, Mar-Aldana R, Ruiz-Ochoa D, Moreno-Graciano C, Martínez-Cruz P. Resultados del Programa de Tamiz Neonatal Ampliado y epidemiología perinatal en los servicios de sanidad de la Secretaría de Marina Armada de México. Acta Pediátr Mex. 2014; 35: 448-458.

  15. Monroy-Santoyo S, Ibarra-González I, Fernández-Lainez C, Greenawalt-Rodríguez S, Chacón-Rey J, Calzada-León R et al. Higher incidence of thyroid agenesis in Mexican newborns with congenital hypothyroidism associated with birth defects. Early Hum Dev. 2012; 88: 61-64.

  16. Al-Thihli K, Al-Murshedi F, Al-Hashmi. N, Al-Mamari W, Islam MM, Al-Yahyaee SA. Consanguinity, endogamy and inborn errors of metabolism in Oman: A cross sectional study. Hum Hered. 2014; 77: 183-188.

  17. Laberge AM, Michaud J, Richter A, Lemyre E, Lambert M, Brais B et al. Population history and its impact on medical genetics in Quebec. Clin Genet. 2005; 68: 287-301.

  18. Klugman S, Gross SJ. Ashkenazi Jewish screening in the twenty-first century. Obstet Ginecol Clin North Am. 2010; 37: 37-46.

  19. Luzzato L, Usanga EA, Reddy S. Glucose-6-phosphate dehydrogenase deficient red cells: Resistance to infection by malarial parasites. Science. 1969; 164: 839-842.

  20. Feuchbaum L, Carter J, Dowray S, Currier RJ, Lorey F. Birth prevalence of disorders detectable through newborn screening by race/ethnicity. Genet Med. 2012; 14: 937-945.

  21. Borrajo GJ. Newborn screening in Latin America at the beginning of the 21st century. J Inherit Metab Dis. 2007; 30: 466-481.

  22. Moreno-Estrada A, Gignoux CR, Fernández-López JC, Zakharia F, Sikora M, Contreras AV et al. Human genetics. The genetics of Mexico recapitulates native American substructure and affects biomedical traits. Science. 2014; 344: 1280-1285.




2020     |     www.medigraphic.com